INTRODUCTION: Papillary thyroid carcinoma (PTC) frequently harbors the BRAF V600E mutation. Recent research suggests that aggressive behavior in BRAF V600E+ PTC may be due to an undetected mutation in the TERT gene. This study aims to observe the clinicopathological features of BRAF V600+ PTC and correlate them with surgical treatment complications. METHODS: A retrospective analysis was conducted on the BRAF V600E+ PTC cohort from July 2019 to January 2023. The histopathological features and surgical treatment (total thyroidectomy - group A, total thyroidectomy + central block neck dissection - group B) complications were correlated. Patients with TERT and TP53 mutation were excluded. Next-generation sequencing and real-time PCR were used for genetic analysis. RESULTS: Out of 121 PTCs, 65 cases showed BRAF V600E mutation with the following features: intracapsular spread (13.8%), extracapsular spread (27.7%), extrathyroidal spread (15.4%), multifocality (26.2%), angioinvasion (12.3%), and local metastasis (27.7%). The incidence of surgical complications in group A/B was: reversible recurrent laryngeal nerve (RLN) paresis 3.7/7.1%, RLN paresis permanent 0/2.4%, paresthesia 6.8/23.8%, hypocalcemia 36.4/61.9% on day 1 and 27.3/33.3% on day 3, and bleeding 2.3/9.5%. There was no significant difference in clinicopathological features between the BRAF V600E+ and BRAF V600E- PTC groups. Group B had a significantly higher incidence of hypoacalcaemia on postoperative day 1 (p = 0.047). CONCLUSION: The BRAF V600E mutation will certainly remain important in the preoperative diagnosis of PTC. The more radical surgical procedures currently recommended may be abandoned in the future, particularly elective CLND, which has a higher risk of postoperative complications.

Charles University 1st Faculty of Medicine and General University Hospital Prague Department of Pathology Prague Czech Republic

Charles University 3rd Faculty of Medicine Prague Czech Republic

Charles University Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove The Fingerland Department of Pathology Hradec Kralove Czech Republic

Institute of Endocrinology Department of Molecular Endocrinology Prague Czech Republic

Masaryk University St Anne's University Hospital Medical Faculty Brno Department of Otorhinolaryngology and Head and NeckSurgery Brno Czech Republic

Military University Hospital Department of Pathology Prague Czech Republic

Military University Hospital Prague Department of Otorhinolaryngology and Maxillofacial Surgery Prague Czech Republic

Zobrazit více v PubMed

Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA (2023). The 2023 Bethesda Systém for Reporting Thyroid Cytopathology. Thyroid 33(9): 1039-1044. DOI: 10.1089/thy.2023.0141. PubMed DOI

Bulanova Pekova B, Sykorova V, Mastnikova K, Vaclavikova E, Moravcova J, Vlcek P, et al. (2023). RET fusion genes in pediatricand adult thyroid carcinomas: cohort characteristics and prognosis. Endocr Relat Cancer 30(12): e230117. DOI: 10.1530/ERC-23-0117. PubMed DOI

Calò PG, Conzo G, Raffaelli M, Medas F, Gambardella C, De Crea C, et al. (2017). Total thyroidectomyalone versus ipsilateral versus bilateral prophylactic central neck dissection in clinically node-negative differentiated thyroid carcinoma. A retrospective multicenter study. Eur J Surg Oncol 43(1): 126-132. DOI: 10.1016/j.ejso.2016.09.017. PubMed DOI

Carty SE, Ohori NP, Hilko DA, McCoy KL, French EK, Manroa P, et al. (2020). The Clinical Utility of Molecular Testing in the Management of Thyroid Follicular Neoplasms (Bethesda IV Nodules). Ann Surg 272(4): 621-627. DOI: 10.1097/SLA.0000000000004130. PubMed DOI

Chen B, Shi Y, Xu Y, Zhang J (2021). The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis. Clin Endocrinol (Oxf) 94(5): 731-742. DOI: 10.1111/cen.14316. PubMed DOI

Cibas ES, Ali SZ (2017). The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 27(11): 1341-1346. DOI: 10.1089/thy.2017.0500. PubMed DOI

Cipriani NA (2019). Prognostic Parameters in Differentiated Thyroid Carcinomas. Surg Pathol Clin 12(4): 883-900. DOI: 10.1016/j.path.2019.07.001. PubMed DOI

Dobrinja C, Troian M, Cipolat Mis T, Rebez G, Bernardi S, Fabris B, et al. (2017). Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center. Int J Surg 41(Suppl 1): S40-S47. DOI:10.1016/j.ijsu.2017.01.113. PubMed DOI

Du E, Wenig BM, Su HK, Rowe ME, Haser GC, Asa SL, et al. (2016). Inter-Observer Variation in the Pathologic Identification of Extranodal Extension in Nodal Metastasis from Papillary Thyroid Carcinoma. Thyroid 26(6): 816-819. DOI: 10.1089/thy.2015.0551. PubMed DOI

Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. (2006). Long-term outcomeof 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of fradioiodine therapy. J Clin Endocrinol Metab 91(8): 2892-2899. DOI: 10.1210/jc.2005-2838. PubMed DOI

Durante C, Hegedüs L, Czarniecka A, Paschke R, Russ G, Schmitt F, et al. (2023). 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. Eur Thyroid J 12(5): e230067. DOI: 10.1530/ETJ-23-0067. PubMed DOI

Feng JW, Qu Z, Qin AC, Pan H, Ye J, Jiang Y (2020). Significance of multifocality in papillary thyroid carcinoma. Eur J Surg Oncol 46(10 Pt A): 1820-1828. DOI: 10.1016/j.ejso.2020.06.015. PubMed DOI

Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. (2019). Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(12): 1856-1883. DOI: 10.1093/annonc/mdz400. PubMed DOI

Furlan JC, Bedard YC, Rosen IB (2004). Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas. J Am Coll Surg 198(3): 341-348. DOI: 10.1016/j.jamcollsurg.2003.11.012. PubMed DOI

Giordano D, Frasoldati A, Gabrielli E, Pernice C, Zini M, Castellucci A, et al. (2017). Long-term outcomes of central neck dissection for cN0 papillary thyroid carcinoma. Am J Otolaryngol 38(5): 576-581. DOI: 10.1016/j.amjoto.2017.06.004. PubMed DOI

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1): 1-133. DOI: 10.1089/thy.2015.0020. PubMed DOI

Iacobone M, Jansson S, Barczyński M, Goretzki P (2014). Multifocal papillary thyroid carcinoma - a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg 399(2): 141-154. DOI: 10.1007/s00423-013-1145-7. PubMed DOI

Jin BJ, Kim MK, Ji YB, Song CM, Park JH, Tae K (2015). Characteristics and signifikance of minimal and maximal extrathyroidal extension in papillary thyroid carcinoma. Oral Oncol 51(8): 759-763. DOI: 10.1016/j.oraloncology.2015.05.010. PubMed DOI

Joseph KR, Edirimanne S, Eslick GD (2018). Multifocality as a prognostic factor in thyroid cancer: A meta-analysis. Int J Surg 50: 121-125. DOI: 10.1016/j.ijsu.2017.12.035. PubMed DOI

Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, et al. (2012). BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 36(2): 310-317. DOI: 10.1007/s00268-011-1383-1. PubMed DOI

Krasner JR, Alyouha N, Pusztaszeri M, Forest VI, Hier MP, Avior G, Payne RJ (2019). Molecular mutations as a possible factor for determining extent of thyroid surgery. J Otolaryngol Head Neck Surg 48(1): 51. DOI: 10.1186/s40463-019-0372-5. PubMed DOI

Li X, Kwon H (2020). The Impact of BRAF Mutation on the Recurrence of Papillary Thyroid Carcinoma: A Meta-Analysis. Cancers (Basel) 12(8): 2056. DOI: 10.3390/cancers12082056. PubMed DOI

Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, et al. (2013). Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20(4): 603-610. DOI: 10.1530/ERC-13-0210. PubMed DOI

Melo M, da Rocha AG, Vinagre J, Sobrinho-Simões M, Soares P (2015). Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis? J Clin Oncol 33(6): 667-668. DOI: 10.1200/JCO.2014.59.4614. PubMed DOI

Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, Dal Maso L (2021). Thyroidcancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol 9(4): 225-234. DOI: 10.1016/S2213-8587(21)00027-9. PubMed DOI

Mukhtar N, Alhamoudi K, Alswailem M, Alhindi H, Murugan AK, Alghamdi B, Alzahrani AS (2023). How do BRAFV600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer? Front Endocrinol (Lausanne) 14: 1270796. DOI: 10.3389/fendo.2023.1270796. PubMed DOI

Nannini M, Repaci A, Nigro MC, Colapinto A, Vicennati V, Maloberti T, et al. (2023). Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer. ESMO Open 8(6): 102039. DOI: 10.1016/j.esmoop.2023.102039. PubMed DOI

Park SY, Kim HI, Kim JH, Kim JS, Oh YL, Kim SW, et al. (2018). Prognostic significance of gross extrathyroidal extension in vading only strap muscles in differentiated thyroid carcinoma. Br J Surg 105(9): 1155-1162. DOI: 10.1002/bjs.10830. PubMed DOI

Paschke R, Cantara S, Crescenzi A, Jarzab B, Musholt TJ, Sobrinho Simoes M (2017). European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics. Eur Thyroid J 6(3): 115-129. DOI: 10.1159/000468519. PubMed DOI

Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. (2012). The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22(11): 1144-1152. DOI: 10.1089/thy.2012.0043. PubMed DOI

Rowe ME, Ozbek U, Machado RA, Yue LE, Hernandez-Prera JC, Valentino A, et al. (2018). The Prevalence of Extranodal Extension in Papillary Thyroid Cancer Based on the Size of the Metastatic Node: Adverse Histologic Features Are Not Limited to Larger Lymph Nodes. Endocr Pathol 29(1): 80-85. DOI: 10.1007/s12022-018-9518-7. PubMed DOI

Siegel RL, Miller KD, Jemal A (2018). Cancerstatistics. CA Cancer J Clin 68(1): 7-30. DOI: 10.3322/caac.21442. PubMed DOI

Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, et al. (2019). Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol 5(2): 204-212. DOI: 10.1001/jamaoncol.2018.4616. PubMed DOI

Tam AA, Özdemir D, Çuhaci N, Başer H, Aydin C, Yazgan AK, et al. (2016). Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer. Endocrine 53(3): 774-783. DOI: 10.1007/s12020-016-0955-0. PubMed DOI

Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, et al. (2017). ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol 14(5): 587-595. DOI: 10.1016/j.jacr.2017.01.046. PubMed DOI

Unlu MT, Aygun N, Demircioglu ZG, Isgor A, Uludag M (2021). Effects of Central Neck Dissection on Complications in Differentiated Thyroid Cancer. Sisli Etfal Hastan Tip Bul 55(3): 310-317. DOI: 10.14744/SEMB.2021.80588. PubMed DOI

Wang F, Yu X, Shen X, Zhu G, Huang Y, Liu R, et al. (2017). The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. J Clin Endocrinol Metab 102(9): 3241-3250. DOI: 10.1210/jc.2017-00277. PubMed DOI

Wreesmann VB, Nixon IJ, Rivera M, Katabi N, Palmer F, Ganly I, et al. (2015). Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. Thyroid 25(5): 503-508. DOI: 10.1089/thy.2015.0052. PubMed DOI

Xing M (2005). BRAF mutation in thyroidcancer. Endocr Relat Cancer 12(2): 245-262. DOI: 10.1677/erc.1.0978. PubMed DOI

Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. (2015). Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 33(1): 42-50. DOI: 10.1200/JCO.2014.56.8253. PubMed DOI

Yip L, Gooding WE, Nikitski A, Wald AI, Carty SE, Karslioglu-French E, et al. (2021). Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study. Cancer 127(11): 1779-1787. DOI: 10.1002/cncr.33421. PubMed DOI

Yu P, Qu N, Zhu R, Hu J, Han P, Wu J, et al. (2023). TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulati ngribosome biogenesis. Sci Adv 9(35): eadg7125. DOI: 10.1126/sciadv.adg7125. PubMed DOI

Zhang Q, Liu SZ, Zhang Q, Guan YX, Chen QJ, Zhu QY (2016). Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma. Cell Physiol Biochem 38(2): 763-776. DOI: 10.1159/000443032. PubMed DOI

Zhao L, Wang L, Jia X, Hu X, Pang P, Zhao S, et al. (2020). The Coexistence of Genetic Mutations in Thyroid Carcinoma Predicts Histopathological Factors Associated With a Poor Prognosis: A Systematic Review and Network Meta-Analysis. Front Oncol 10: 540238. DOI: 10.3389/fonc.2020.540238. PubMed DOI